Acrux begins anti-nausea trial
Wednesday, 02 March, 2005
Acrux (ASX:ACR) has commenced dosing in a Phase I clinical trial utilising its MDTS transdermal spray to deliver anti-nausea drug granisetron. The pharmacokinetics trial will compare absorption of the drug, which is used to treat nausea in chemotherapy patients, against that of an oral formulation in six healthy volunteers.
"Prevention of nausea during chemotherapy with a product that does not require injections or tablets would help minimise distress for cancer patients," said Acrux CEO Igor Gonda. Brisbane-based CRO Q-Pharm is conducting the trial in its clinical trials facilities at the Royal Brisbane Hospital for Acrux subsidiary Acrux DDS.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
